Health
Leonard Hayflick, Who Discovered Why No One Lives Forever, Dies at 98
Leonard Hayflick, a biomedical researcher who discovered that normal cells can divide only a certain number of times — setting a limit on the human life span and frustrating would-be-immortalists everywhere — died on Aug. 1 at his home in Sea Ranch, Calif. He was 98.
His son, Joel Hayflick, said the cause was pancreatic cancer.
Like many great scientific findings, Dr. Hayflick’s came somewhat by accident. As a young scientist in the early 1960s at the Wistar Institute, a research organization at the University of Pennsylvania, he was trying to develop healthy embryonic cell lines in order to study whether viruses can cause certain types of cancer.
He and a colleague, Paul Moorhead, soon noticed that somatic — that is, nonreproductive — cells went through a phase of division, splitting between 40 and 60 times, before lapsing into what he called senescence.
As senescent cells accumulate, he posited, the body itself begins to age and decline. The only cells that do not go into senescence, he added, are cancer cells.
As a result of this cellular clock, he said, no amount of diet or exercise or genetic tweaking will push the human species past a life span of about 125 years.
This finding, which the Nobel-winning virologist Macfarlane Burnet later called the Hayflick limit, ran counter to everything scientists believed about cells and aging — especially the thesis that cells themselves are immortal, and that aging is a result of external causes, like disease, diet and solar radiation.
Other researchers later discovered the mechanisms behind the Hayflick limit: As cells divide, they create copies of DNA strands, but the ends of each copy, called the telomeres, are a bit shorter than the last. Eventually the telomere runs out, and the cell stops dividing.
Dr. Hayflick made other important contributions to science. He developed a particularly vibrant cell line, WI-38, which has been used for decades to make vaccines. He also discovered that so-called walking pneumonia, unlike regular pneumonia, is caused not by a virus but by a type of mycoplasma, the smallest form of free-living organism.
But it was his work on aging that established his legacy. Dr. Hayflick was an outspoken critic of those who thought they could unlock the science of eternal life; he considered that idea an illusion and the pursuit of it a folly, if not outright fraud.
“The invention of ways to increase human longevity is the world’s second-oldest profession, or maybe even the first,” he told the medical journal The Lancet in 2011. “Individuals are going to the bank at this moment with enormous sums of money gained by persuading people that they’ve found either a way to extend your life or to make you immortal.”
Leonard Hayflick was born on May 20, 1928, in Philadelphia to Nathan Hayflick, who made dental prosthetics, and Edna (Silver) Hayflick, who worked in his father’s office.
He enrolled at the University of Pennsylvania but took three years off to serve in the Army. He graduated with a degree in microbiology in 1951, and five years later received a Ph.D. in chemistry and microbiology there.
After two years as a postdoctoral fellow at the University of Texas Medical Branch at Galveston, he returned to Penn and the Wistar Institute, where he made many of his most important discoveries. He continued that work at Stanford University in 1968.
There was a wrinkle, though. The National Institutes of Health had funded the research on his WI-38 cell line but declined to fund its distribution, even as other researchers clamored for samples. Dr. Hayflick established a company to process orders, charged a minimal fee for shipping and set the proceeds aside until ownership was clarified.
But in a private report that was released to the news media, the N.I.H. accused Dr. Hayflick of theft. He sued the institute, charging invasion of privacy and reputational damage, including a forced resignation from his position at Stanford. The litigation took six years and ended in a settlement that allowed him to keep some of the money and cell samples.
During those six years, Congress passed the Bayh-Dole Act, which allows scientists to profit off government-funded research. The law, which would have made Dr. Hayflick’s earlier actions unquestionably legal, helped catalyze the biotech industry.
Dr. Hayflick married Ruth Heckler in 1955. She died in 2016. Along with his son, he is survived by four daughters, Deborah Curle, Susan Hayflick, Rachel Hastings and Annie Hayflick; eight grandchildren; and his sister, Elaine Rosamoff.
Dr. Hayflick later worked at the University of Florida and, since 1988, at the University of California, San Francisco, where he was an emeritus professor.
His criticism of those trying to find ways to extend the human life span was not just about practicality. On principle he thought it was a terrible idea.
“I’m an optimist,” he told The Guardian in 2001. “Anyone who believes in manipulating the human aging process is a terrible pessimist. I don’t want to be alive when that’s possible. I don’t want to give another Adolf Hitler, a Saddam Hussein, another 50 years of life.”
He continued, “Every time someone like that dies a natural death, people should thank their God, whoever that might be, for the phenomenon of aging.”
NEWYou can now listen to Fox News articles!
A new test could make it easier to detect high-risk prostate cancer cases earlier.
The blood test, called Stockholm3, is showing promise in clinical trials, beating out the traditional, standard prostate-specific antigen (PSA) test.
In a new study published in the Annals of Internal Medicine, researchers from the Karolinska Institutet in Sweden studied the test’s efficacy in more than 12,000 men — mostly Swedish or European — aged 50 to 74.
NEW PROSTATE CANCER TEST PINPOINTS DISEASE BETTER THAN PSA OPTION, STUDY FINDS
All participants were tested with PSA and Stockholm3 and were followed for two years. During the follow-up period, 443 men were diagnosed with aggressive prostate cancer.
Stockholm3 detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests.
Stockholm3 detected 90% of aggressive prostate cancer cases compared to 74% for PSA tests. (iStock)
Stockholm3 missed “significantly fewer” serious cancer cases than PSA. The number of men incorrectly classified as high-risk was similar across both tests, according to a press release.
Thorgerdur Palsdottir, a researcher at the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, wrote in a statement that one of the major challenges in prostate cancer is being able to identify the cases that are “truly dangerous.”
‘DILBERT’ CREATOR’S DESPERATE PLEA SHINES SPOTLIGHT ON ALTERNATIVE PROSTATE CANCER DRUG
“Our results show that Stockholm3 identifies significantly more aggressive cancer cases than PSA without increasing the number of unnecessary follow-ups,” she said.
“These results point toward a potential change in how prostate cancer screening can be conducted,” the researcher added. “A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures.”
“A more precise blood test could enable earlier detection of aggressive disease while reducing the number of unnecessary follow-up examinations and procedures,” a researcher commented. (iStock)
Study co-author Hari Vigneswaran, chief medical officer of Stockholm3-maker A3P Biomedical, commented on these “promising” findings in an interview with Fox News Digital.
PROSTATE CANCER SCREENING AFTER 70: EXPERTS QUESTION GUIDANCE AFTER BIDEN’S DIAGNOSIS
He confirmed that the PSA has been the standard for prostate cancer screening since the 1990s despite its “well-documented limitations.”
CLICK HERE FOR MORE HEALTH STORIES
“It leads to invasive and costly follow-up testing, contributes to over-diagnosis of non-aggressive cancers and, most importantly, it misses a substantial share of aggressive disease,” Vigneswaran said.
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival is close to 100%. (iStock)
When aggressive prostate cancer is found while still confined in the prostate, the five-year survival rate is close to 100%, which highlights the importance of early detection, according to the doctor.
TEST YOURSELF WITH OUR LATEST LIFESTYLE QUIZ
Data from the National Cancer Institute’s SEER database show that metastatic prostate cancer has risen over the past decade, suggesting that “we have not improved early detection of the aggressive, curable disease that screening is meant to catch,” Vigneswaran said.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
“The goal of screening is to find the cancers that need treatment while they are still curable, without raising the number of men who screen positive but don’t have aggressive disease,” he said.
Stockholm3 could reduce the need for unnecessary MRIs and biopsies, according to the researcher. (Getty Images)
Stockholm3 could reduce the need for unnecessary MRIs and biopsies, according to the researcher.
The findings did have some limitations. Stockholm3 is an investigational device and is not available for sale in the U.S., Vigneswaran noted.
CLICK HERE TO SIGN UP FOR OUR HEALTH NEWSLETTER
The test estimates a man’s risk of aggressive prostate cancer, but a biopsy remains the gold standard for confirming the disease.
The company plans to seek FDA approval to use the test for routine screening and will “generate the evidence needed to support that pathway, including U.S. data,” Vigneswaran said.
Use left and right arrow keys to navigate between menu items.
Use escape to exit the menu.
Sign Up
Create a free account to access exclusive content, play games, solve puzzles, test your pop-culture knowledge and receive special offers.
Already have an account? Login
NEWYou can now listen to Fox News articles!
Scientists have linked eating leafy green vegetables such as spinach, kale and broccoli to better lung health.
There are two primary forms of vitamin K found in foods. The primary kind is vitamin K1, found mainly in vegetables, which plays a major role in the body’s blood-clotting process.
CLICK HERE FOR MORE LIFESTYLE STORIES
Vitamin K2 is found in fermented foods, certain dairy products, eggs and meats and helps regulate calcium in the body and supports bone health.
Researchers at Australia’s Edith Cowan University examined whether dietary intake of vitamins K1 and K2 was associated with chronic obstructive pulmonary disease (COPD), asthma and lung function.
Leafy green vegetables are high in vitamin K1, a nutrient that researchers have observed conributes to improved lung health. (iStock)
“Chronic respiratory diseases, including chronic obstructive pulmonary disease (COPD) and asthma, are among the most prevalent noncommunicable diseases worldwide and were the third leading cause of death in 2019, accounting for 4 million deaths and affecting 454.6 million individuals globally,” the scientists reported in the introduction to their study, published in The American Journal of Clinical Nutrition.
“Although asthma and COPD can be managed with available treatments, neither condition is curable, underscoring the need for effective prevention strategies,” they added.
The leading cause of COPD is smoking, the Mayo Clinic reported. Exposure to other irritants, such as dust, chemicals and pollution, can also cause it.
The researchers analyzed data from 179,062 participants over a 10-and-a-half-year period and concluded that, “Higher dietary vitamin K1 intake was associated with better lung function and a lower rate of COPD.”
Researchers found that people who increased their vitamin K1 intake were less likely to develop COPD. (iStock)
Participants who consumed the most vitamin K1 had a 16% lower likelihood of COPD, the researchers observed. The effects were more pronounced in smokers and participants with high-risk occupations.
Consumption of vitamin K2 did not result in lower COPD rates.
“No association was observed for vitamin K1 or vitamin K2 intakes and asthma,” the researchers also wrote.
CLICK HERE FOR MORE LIFESTYLE STORIES
Associate Professor Marc Sim, who was involved in the study, said that it’s likely Vitamin K activates a protein that may help keep lung tissue flexible and prevent damage.
Because the study was observational, it cannot prove that vitamin K1 directly reduces COPD risk, only that higher intake was associated with better lung health.
Researchers have associated higher consumption of leafy green vegetables with better lung function. (iStock)
Just one extra serving of leafy greens “is an achievable way to boost your vitamin K1 intake,” said Chengfeng Li, one of the study’s researchers.
CLICK HERE TO DOWNLOAD THE FOX NEWS APP
Other foods rich in vitamin K1 include collard greens, Swiss chard, Brussels sprouts and turnip greens.
-
North Carolina1 minute ago
NC Lottery Powerball, Pick 3 Day results for June 27, 2026
-
North Dakota4 minutes agoPreparations for President’s North Dakota visit begin
-
Ohio9 minutes agoOhio State football single game tickets now on sale | Buckeyes Wire
-
Oklahoma16 minutes agoOklahoma Lottery Powerball, Lotto America results for June 27, 2026
-
Oregon19 minutes agoVisit Delicious Oregon
-
Pennsylvania24 minutes agoAmerica250 history trail: Visit Pennsylvania’s overlooked sites that helped win the American Revolution
-
Rhode Island31 minutes agoLego convention returns to Warwick
-
South-Carolina34 minutes agoWhat exactly was Ted Cruz doing in SC for Alan Wilson? Dreaming of the White House, perhaps.
